A urethral indwelling continuous drug delivery device

Abstract

The invention provides a urethral indwelling continuous drug delivery device, which mainly relates to the field of urology. A urethral indwelling continuous drug delivery device, comprising a medicine supply box, an indwelling part and a collection device, the medicine supply box including a box body, a pump body, a control device and a power supply, and the indwelling part including a cannula, an insertion tube and a drug tube , one end of the sleeve tube is provided with a silicone strip bonded to the skin, a connecting belt is set between the silicone strip and the sleeve tube, and the insertion tube is inserted into the inside of the sleeve tube from the end of the sleeve tube away from the silicone strip, and the insertion tube is used for It is inserted into the urethra, the top of the insertion tube is sealed, the outlet of the drug tube is screwed to the bottom of the insertion tube, and the collection device includes a second fixing device and a fluid collection bag. The beneficial effect of the present invention is that: the present invention can carry out continuous administration to the urethra, so that the medicine can continuously and directly contact the affected part, the continuous administration shortens the recovery time greatly, and also solves the problem of mutual adhesion at the damaged part of the urethra.

Description

technical field [0001] The invention mainly relates to the field of urology, in particular to a urethral indwelling continuous drug delivery device. Background technique [0002] Male urinary system diseases have always been an important problem that plagues men's physical health. Problems in the male urinary system often lead to external symptoms such as frequent urination, urgency, dysuria, and urinary incontinence, and may also be accompanied by high blood pressure, edema, and anemia. and other symptoms, which seriously endanger the physical and mental health of men. In severe cases, male urinary tract infection and urethral inflammation can lead to serious health problems such as urethral damage and pus discharge, and urethral adhesions, which greatly affect the physical health of men. At present, the main treatment methods for urethral inflammation include oral administration of anti-inflammatory drugs, subcutaneous injection of anti-inflammatory drugs and urethral adm...

AI Technical Summary

Problems solved by technology

At present, the treatment methods for urethral inflammation mainly include oral anti-inflammatory drugs, subcutaneous injection of anti-inflammatory drugs and urethral administration. The active ingredients of these two methods of oral anti-inflammatory drugs and subcutaneous injection of anti-inflammatory drugs need to pass through the digestive system or lymphatic system. It takes a long time to take effect, and the recovery of the affected area is slow. Although the way of urethral administration allows the drug to directly contact the affected area, due to the special physiological structure of men, the drug is not easy to indwell in the male urethra, which also affects treatment effect

Just like the invention patent with the application number CN201610020154.6 and the name "A Urethral Drug Delivery Device for Urology", the urethral inflammation is treated by injecting drugs into the urethra. After the drugs are injected into the patient's urethra, they cannot Long-term retention in the urethra, the treatment effect is not ideal

[0003] To sum up, at present, there are still problems of slow effect on male urethral inflammation, long recovery time, unsustainable administration of urethra, and unsolvable problems of urethral adhesion

Images